Many correlations between high YAP and TAZ expression with poor patient outcome were reported for breast, colorectal, liver, and pancreatic cancers [87]; specifically, TAZ is thought to play an important role in breast cancer progression, with both mRNA and protein expression reported to be preferentially higher in triple-negative breast cancer than in the other subclasses [116,117,118,119]. Here, YAP1 is linked to breast cancer.